导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.20% | 2538/4773 |
| 近一周 | -2.36% | 1933/5462 |
| 近一月 | -8.10% | 4103/5421 |
| 近一季 | 10.38% | 158/5209 |
| 近半年 | 1.47% | 1044/4920 |
| 近一年 | -13.22% | 3595/4366 |
| 近两年 | 24.41% | 2528/2954 |
| 近三年 | -3.85% | 1981/2253 |
| 成立以来 | 13.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.08% 2110/4961 |
-3.47% 3455/5312 |
- - |
- - |
| 2025 | 9.91% 2843/4813 |
2.42% 1376/3635 |
2.40% 1592/4076 |
18.95% 2217/4524 |
-11.91% 4220/4813 |
| 2024 | -11.83% 2361/3463 |
-12.19% 2450/2808 |
-8.94% 2306/3014 |
19.19% 874/3129 |
-7.49% 2764/3463 |
| 2023 | -10.19% 1274/2656 |
-0.82% 1828/2280 |
-7.33% 1836/2385 |
0.24% 378/2515 |
-2.52% 486/2655 |
| 2022 | -22.58% 1074/2207 |
-10.74% 414/1919 |
-2.41% 1776/2016 |
-18.85% 1741/2113 |
9.52% 212/2208 |
| 2021 | -13.63% 1138/1822 |
-3.21% 783/1255 |
8.23% 642/1330 |
-13.68% 1355/1466 |
-4.49% 1485/1822 |
| 2020 | 46.80% 203/1250 |
6.18% 46/1028 |
28.34% 109/1067 |
3.40% 984/1164 |
4.18% 858/1184 |
| 2019 | 29.43% 503/1092 |
26.86% 372/754 |
-7.73% 572/804 |
5.61% 142/850 |
4.70% 788/918 |
| 2018 | -24.02% 312/834 |
- - |
- - |
- - |
-18.92% 660/691 |
| 2017 | 18.02% 212/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.34% 281/605 |
- - |
- - |
- - |
- - |
| 2015 | 33.27% 67/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安中证细分医药ETF联接C VS. 长安沪深300非周期A(740101) |